The European Medicines Agency (EMA) on Thursday said it had started reviewing a Covid-19 jab by Franco-Austrian biotech firm Valneva, for which the EU has already signed a deal for 60 million doses.

“EMA’s human medicines committee has started a rolling review of VLA2001, a Covid-19 vaccine being developed by Valneva,” the regulator said in a statement, adding that it could not yet say when a decision on approval might come.